ALK-Abelló
A pharmaceutical company specializing in allergy prevention, diagnosis, and treatment.
ALK | CO
Overview
Corporate Details
- ISIN(s):
- DK0061802139
- LEI:
- 529900SGCREUZCZ7P020
- Country:
- Denmark
- Address:
- Bøge Alle 6-8, 2970 Hørsholm
- Website:
- https://www.alk.net
- Sector:
- Manufacturing
Description
ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2024-02-08 13:35 | English | HTML • 11.6 KB | |||
| 2024-02-08 13:35 |
Annual report 2023: ALK delivers 9% sales growth with profits up 50%
|
Danish | PDF • 4.7 MB | ||
| 2024-01-18 15:34 | English | PDF • 215.0 KB | |||
| 2024-01-18 15:34 | Danish | HTML • 6.0 KB | |||
| 2024-01-18 15:34 |
ALK completes first part of phase 1 trial with peanut SLIT-tablet
|
Danish | PDF • 135.5 KB | ||
| 2024-01-18 15:34 |
ALK completes first part of phase 1 trial with peanut SLIT-tablet
|
Danish | HTML • 5.7 KB | ||
| 2023-12-12 16:08 | English | HTML • 4.5 KB | |||
| 2023-12-12 16:08 | Danish | PDF • 127.1 KB | |||
| 2023-12-12 16:08 |
ALK expands partnership with Torii in Japan
|
Danish | HTML • 4.9 KB | ||
| 2023-12-12 16:08 |
ALK expands partnership with Torii in Japan
|
Danish | PDF • 127.9 KB | ||
| 2023-10-11 16:13 | Danish | PDF • 209.1 KB | |||
| 2023-10-11 16:13 | English | PDF • 205.7 KB | |||
| 2023-10-11 16:13 |
Large Phase 3 clinical trial successfully meets primary endpoint, confirming th…
|
Danish | HTML • 6.0 KB | ||
| 2023-10-11 16:13 |
Large Phase 3 clinical trial successfully meets primary endpoint, confirming th…
|
Danish | HTML • 5.5 KB | ||
| 2023-08-24 07:30 | English | HTML • 10.3 KB |
Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ALK-Abelló
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ALK-Abelló via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
